[HTML][HTML] μ-opioid receptor agonists and psychedelics: pharmacological opportunities and challenges
LM Salinsky, CR Merritt, JC Zamora… - Frontiers in …, 2023 - frontiersin.org
Opioid misuse and opioid-involved overdose deaths are a massive public health problem
involving the intertwined misuse of prescription opioids for pain management with the …
involving the intertwined misuse of prescription opioids for pain management with the …
[HTML][HTML] Psychedelics: threshold of a therapeutic revolution
DJ Heal, SL Smith, SJ Belouin, JE Henningfield - Neuropharmacology, 2023 - Elsevier
ABSTRACT This Special Issue of Neuropharmacology on psychedelics provides a timely
and comprehensive update on progress following the previous Neuropharmacology Special …
and comprehensive update on progress following the previous Neuropharmacology Special …
Psilocybin restrains activity-based anorexia in female rats by enhancing cognitive flexibility: contributions from 5-HT1A and 5-HT2A receptor mechanisms
Psilocybin has shown promise for alleviating symptoms of depression and is currently in
clinical trials for the treatment of anorexia nervosa (AN), a condition that is characterised by …
clinical trials for the treatment of anorexia nervosa (AN), a condition that is characterised by …
[HTML][HTML] Knowledge gaps in psychedelic medicalisation: Preclinical and neuroimaging mechanisms
Classical psychedelic drugs, eg, psilocybin and LSD, stimulate the serotonin 2A receptor (5-
HT2AR) and have recently been intensely investigated for their clinical effects in various …
HT2AR) and have recently been intensely investigated for their clinical effects in various …
Psilocybin prevents activity-based anorexia in female rats by enhancing cognitive flexibility: contributions from 5-HT1A and 5-HT2A receptor mechanisms
Psilocybin has shown promise for alleviating symptoms of depression and is currently in
clinical trials for the treatment of anorexia nervosa (AN), a condition that is characterised by …
clinical trials for the treatment of anorexia nervosa (AN), a condition that is characterised by …
Gβγ subunit inhibitor decreases DOM-induced head twitch response via the PLCβ/IP3/Ca2+/ERK and cAMP signaling pathways
H Zhu, X Liu, X Wang, Y Li, F Ma, B Tan, P Zhou… - European Journal of …, 2023 - Elsevier
Abstract Aims (−)-2, 5-dimethoxy-4-methylamphetamine (DOM) induces the head-twitch
response (HTR) primarily by activating the serotonin 5-hydroxytryptamine 2A receptor (5-HT …
response (HTR) primarily by activating the serotonin 5-hydroxytryptamine 2A receptor (5-HT …
Deciphering psilocybin: Cytotoxicity, anti-inflammatory effects, and mechanistic insights
S Laabi, C LeMmon, C Vogel, M Chacon… - International …, 2024 - Elsevier
A decade of clinical research has indicated psilocybin's effectiveness in treating various
neuropsychiatric disorders, such as depression and substance abuse. The correlation …
neuropsychiatric disorders, such as depression and substance abuse. The correlation …
Exploring Next-Generation Therapeutics: Morphic Mixtures and Specified Salts for the Treatment of Mental Disorders and CNS Modulation
RB Kargbo - ACS Medicinal Chemistry Letters, 2023 - ACS Publications
This Patent Highlight delves into the potential of next-generation therapeutics for treating
mental disorders and modulating the central nervous system (CNS). Among the serotonin …
mental disorders and modulating the central nervous system (CNS). Among the serotonin …
[PDF][PDF] Knowledge gaps in psychedelic medicalisation: Preclinical and neuroimaging mechanisms
Classical psychedelic drugs, eg, psilocybin and LSD, stimulate the serotonin 2A receptor (5-
HT2AR) and have recently been intensely investigated for their clinical effects in various …
HT2AR) and have recently been intensely investigated for their clinical effects in various …
Psilocybin-enhanced fear extinction linked to bidirectional modulation of cortical ensembles
The serotonin 2 receptor (5HT2R) agonist psilocybin has demonstrated rapid and long-
lasting efficacy across neuropsychiatric disorders characterized by cognitive inflexibility …
lasting efficacy across neuropsychiatric disorders characterized by cognitive inflexibility …